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Reproducibility of Exercise Testing in Patients with Pulmonary Arteriovenous
Malformations
Bolin Niu, Walter Li, Katharine Henderson, Veronika Northrup, Jeffery S. Pollak,
Terence Trow, John Fahey, and Robert I. White, Jr. Department of Diagnostic
Radiology, Yale University, School of Medicine, New Haven, CT.
Patients with pulmonary arteriovenous malformations (PAVMs) are at risk for
complications, hemorrhagic and neurological, and therefore require close follow-up.
The primary hypothesis of this project poses that the exercise stress test (EST)
and 6-minute walk test (6MWT) are reproducible and reliable in patients with PAVMs.
Secondarily, if these tests are shown to be reproducible, they may become a surrogate
follow-up tool for patients with PAVMs after quantification with non-contrast CT and
may replace contrast echocardiography in asymptomatic children under age 12.
Twenty-two patients with PAVMs, most of whom had hereditary hemorrhagic
telangiectasia (HHT), participated in a Human Investigations Committee-approved
protocol. Patients ranged from 9 to 74 years of age (mean 28) and had a broad spectrum
of anatomic subtypes of PAVMs, including focal and diffuse. Standard 6MWT and cycle
ergometry EST were both performed twice with adequate rest between tests. Heart rate
(HR) and oxygen saturation were measured at the beginning and end of each test.
Distance walked and maximum resistance were also recorded. The intraclass correlation
coefficients (ri) at the end of 6MWT were as follows: HR (ri = 0.940; 95% CI = 0.8630.975), post test oxygen saturations (ri = 0.973; 95% CI = 0.933-0.989), distance walked
(ri = 0.942; 95% CI = 0.867-0.975). The ris at the end of EST were as follows: HR (ri =
0.941; 95% CI 0.865–0.975), oxygen saturation (ri = 0.993; 95% CI 0.982–0.997), and
maximum resis- tance (ri = 0.941; 95% CI 0.864–0.975). 6MWT and EST were
reproducible measures of exercise capacity and oxygen saturation and are potential
adjunct tests in the follow-up assessment for patients with PAVMs.
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Introduction
Background on pulmonary arteriovenous malformations
Pulmonary arteriovenous malformations (PAVMs) were first described by
Churton in 1897 (1). PAVMs are abnormal thin-walled vascular communications
between pulmonary veins and arteries. As thin-walled vascular dilations, PAVMs may
rupture and cause pulmonary hemorrhage (2,3). PAVMs are extracardiac right-to-left
shunts, allowing blood to bypass the capillary filtration system in the lungs. PAVMs are
a route that allows the passage of paradoxical emboli into the systemic circulation.
Neurologic consequences such as transient ischemic attack, cerebrovascular accident, and
cerebral abscess occur as a result of PAVMs (4).
Historical evidence and experience at the Yale Hereditary Hemorrhagic
Telangiectasia (HHT) Center shows greater than 70% of patients with PAVMs have
underlying HHT (2,5,6). An autosomal dominant genetic disease with mutations in the
protein endoglin (type 1) and activin receptor-like kinase (type 2), HHT involves many
organ systems through arteriovenous malformations in the lungs (7), brain (8), liver (9),
GI tract (10), and uncommonly in the retina (11). The phenotypic manifestations of HHT
may prompt the clinician to investigate the possibility of PAVMs and vice versa. In fact,
PAVMs are the leading cause of morbidity and mortality among patients with HHT (12).

Current guidelines on treatment of pulmonary arteriovenous malformations
Treatment of PAVMs has three main goals: 1) prevention of paradoxical
embolization, 2) prevention of consequences of pulmonary hemorrhage such as
hemothorax or hemoptysis, and 3) improving symptomatic dyspnea or exercise
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intolerance.
The “International Guidelines for the Diagnosis and Management of Hereditary
Hemorrhagic Telangiectasia” published in 2011 recommends transcatheter embolization
as primary treatment for PAVMs as it has been shown to be efficacious and safe with rare
complications (2,13–17). The selection of PAVMs for embolization is based on feeding
artery diameter, generally 3mm or greater due to neurologic complications associated
with paradoxical emboli (14,18). The HHT center at Yale reported on a series of 415
PAVMs occluded in a period of three years (14). Clinical and imaging follow-up were
available in all patients. Radiographic imaging showed pulmonary AVM involution in
97% of embolized lesions (14).
Albeit rare at 2%, the procedure of transcatheter embolotherapy comes with some
complications as well, including angina, transient ischemic attack, and pleurisy
(14,19,20). In addition, reperfusion of PAVMs may recur after transcatheter
embolization (14).

Current guidelines on screening and follow-up of pulmonary arteriovenous
malformations
The current guidelines recommends using transthoracic contrast
echocardiography as initial screening test for PAVMs (17). Contrast echocardiography
has been demonstrated to be reliable as a predictor of PAVMs, and a correlation has been
shown to exist between contrast echocardiography grade and probability of PAVMs (19).
Positive screening with contrast echocardiography is followed by unenhanced
multidetector thoracic CT with thin-cut reconstructions (17). However, the choice of
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screening tests is unclear in children. Current recommendations leave the decision to the
clinician on a case by case basis. From parent reports at our institution, children with
HHT often receive chest CTs in place of detailed history and physicals at outside
hospitals and emergency departments especially.
The guidelines also recommends long-term follow-up for patients with PAVMs to
detect growth of untreated PAVMs and any reperfusion of treated ones (17). There is no
recommendation for methods of follow-up for children with untreated PAVMs. For
adults, the follow-up schedule after transcatheter embolization includes an unenhanced
CT at 6 months and then every 3 years after embolization (17). Transthoracic contrast
echocardiography has been shown to not be useful after embolization, as it remains
positive in 90% of patients post-repair (20).

Exercise testing for patients with diffuse pulmonary arteriovenous malformations
Pulmonary arteriovenous malformations can be grouped into similar categories
depending on distribution in the lungs. The anatomy of PAVMs is crucial in its
involution because successful elimination of the PAVM requires embolization of all
feeding arteries.
A simple PAVM involves one or branches from the same pulmonary segmental
artery, whereas a complex PAVM involves contributing branches from more than one
segmental artery. Diffuse disease is signified by an entire segmental artery having small
PAVMs diffusely (21). Approximately 55% of patients have simple PAVMs, 40% have
complex and simple, and 5% have diffuse disease involvement (22). Diffuse disease may
have unilateral or bilateral involvement of the lung (21,23). Patients with a diffuse
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pattern of involvement have a higher incidence of complications including brain abscess
compared to patients with focal disease (21).
Initially, non-contrast CT was used as the main method to identify large focal
PAVMs that occurred in some diffuse patients. Diffuse patients with large focal PAVMs
need to be treated with transcatheter embolization to prevent complications from
paradoxical emboli and hemoptysis. These patients with a high-risk natural history need
yearly follow up (23). Unenhanced CT was not as useful in follow-up imaging to detect
changes of diffuse PAVMs (21,23).
Six years ago, frustrated by the inability of unenhanced CT to define progression
or predict deterioration, the Yale center examined exercise testing data from 40 diffuse
patients. Serendipitously, the results showed stability of exercise tolerance from year to
year in patients who were evaluated with exercise stress test with increasing interval
resistance cycle ergometer (23,24). Patients exhibited a change in their exercise test
results only when symptoms deteriorated with enlargement of PAVMs; they showed an
increased fall in oxygen saturation during exercise (24).
Therefore, our institution began evaluating both those with diffuse and focal
PAVMs with cardiorespiratory exercise using a cycle ergometer. We have established
exercise stress testing (EST) as a safe and non-invasive method to monitor patients with
diffuse PAVMs (24). Serial EST showing increasing oxygen desaturation during
exercise correlates with decreased functionality (24).

Previous literature on exercise stress test (EST) and 6-minute walk test (6MWT)
Intrapulmonary shunts allow cyanotic blood to return to systemic circulation
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deoxygenated. PAVMs are a form of intrapulmonary shunts due to abnormal vessel
formations between the pulmonary arteries and veins that bypass the pulmonary capillary
bed and allow right to left shunting of blood. The degree of cyanosis varies with the
amount of right-to-left shunt through intrapulmonary shunts. When the flow of blood
through intrapulmonary shunts is a small fraction of the total cardiac output, the cyanosis
may not be significant at rest.
However, strenuous exercise will result in lowering the systemic venous oxygen
content further and, thus, the systemic oxygen saturation. When the returning systemic
mixed venous oxygen content is decreased further in exercise, the cyanosis will be
worsened. As opposed to patients with chronic lung disease, exercise tolerance is
relatively well-maintained (70% of predicted maximum heart rate) in PAVM patients,
and no complications have previously been reported in adult PAVM patients undergoing
EST (25).
6MWT has been shown to be a reliable and valid functional test for assessing
exercise tolerance and endurance in a study of 78 Chinese secondary school students
(26). While studies of reliability and validity of exercise testing have been shown in
healthy children and adults (26,27), there has not been a demonstration of the
reproducibility of 6MWT in patients with PAVMs.
Another study assessed exercise tolerance and oxygen saturation in severely ill
children awaiting heart-lung or lung transplantation by comparing the 6MWT and EST
results (28). The results showed close correlation of the minimum oxygen saturations
during the 6MWT and EST (28). Furthermore, reduced muscle mass in patients who are
chronically ill may lead to early thigh muscle fatigue, which limits their ability to
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overcome pedal resistance (28). Whereas, walking uses overall muscle mass and shows
less localized muscle fatigue (28). The study concluded that the 6-minute walk test
provides an alternative method for measuring functional capacity in chronically ill
children with limited exercise tolerance (28). In short, the 6MWT has the added
advantage of simplicity to administer, less expense, and avoidance of patient fatigue, all
of which are of great benefit for our elderly and more ill patients with PAVMs.
Various case studies have observed the increase in oxygen saturation during
exercise of patients after repair of pulmonary arteriovenous fistulas (29,30). One such
study of a 16-year-old girl, who had a 2cm long fistulous connection between the right
intermediate pulmonary artery and the right upper pulmonary vein that varied with a
diameter of 6-13mm, was treated with transcatheter embolization of the fistula and
exercise testing thereafter (30). At EST before the procedure, her oxygen saturation was
92% and decreased to 79% with exercise (30). At follow-up six months after
embolization, her oxygen saturation was 99% and decreased to 97% with exercise (30).
In a 2002 study, EST was used before and after transcatheter embolization in
patients with PAVMs. Patients reported an improvement after embolization in exercise
capacity in daily living (31). The study reported a median increase of 3.5% in the oxygen
saturation at maximal exercise after PAVM repair compared to before (31). This study
shows the growing interest in using exercise testing to monitor patients with PAVM, and
it mimics our observations that elimination of right-to-left shunting results in higher
oxygen saturations and more efficient gas exchange during exercise.
Nevertheless, EST and the standard 6MWT have not been shown to be
reproducible in patients with PAVMs.
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Statement of Purpose and Hypothesis
PAVMs are the leading cause of morbidity and mortality among patients with
hereditary hemorrhagic telangiectasia (12,32). The overall degree of shunting from
PAVMs depends on hemoglobin level, vascular resistance of the PAVM and pulmonary
arterioles, and systemic mixed venous oxygen saturation. Therefore, patients may or may
not show signs of cyanosis or clubbing despite having PAVMs; nevertheless, they remain
at risk for morbid conditions such as stroke, brain abscesses, hemothorax, and
hemoptysis.
Previous reports from the Yale HHT center showed that arterial oxygen saturation
often decreases during EST, most likely due to increased extraction of oxygen and
decrease in systemic mixed venous oxygen content (24). However, the reliability and
reproducibility of EST and 6MWT have yet to be demonstrated.
The primary hypothesis of this project is that the exercise stress test (EST) and 6minute walk test (6MWT) are reproducible and reliable in patients with PAVMs.
Secondarily, if both of these standard tests are shown to be reliable and reproducible in
patients with all types of PAVMs, then EST and 6MWT:
1) may become a surrogate for adolescent and adult patients with small PAVMs
after quantification with non-contrast CT,
2) may replace contrast echocardiography in asymptomatic HHT children under
12 or if parents are concerned since the data on contrast echocardiography
indicates grade 1 or less would not warrant treatment.
3) If serial EST and 6MWT demonstrate no worsening of shunts after a patient's
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PAVMs are repaired, EST and 6MWT could be used as routine follow-up
tools for the assessment of PAVM recurrence or enlargement.
Thus, this could lead to reduction of the use of chest CT and, ultimately, decrease
the financial and radiation burden on individual patients while continuing to monitor for
the presence of clinically significant PAVMs in HHT patients and providing reassurance
to their families. The reason for validating two different exercise tests is because the
6MWT is familiar to adult pulmonologists and often used for adult pulmonary disease,
whereas, the cycle ergometry EST is frequently employed by pediatric cardiologists.
Therefore, patients may be seen by a pulmonologist or a cardiologist for follow-up.

Subjects and Methods
Subject selection
Twenty-two subjects were included in this study. All patients at the Yale HHT
center undergoing either evaluation before transcatheter embolotherapy or follow-up after
transcatheter embolotherapy for previously identified PAVMs were offered participation
in the study. A detailed history of present illness, past medical history, family history,
and physical exam were performed in office. Physical exam findings that were noted
include telangiectasias, clubbing, and/or cyanosis. Standing oxygen saturations were
obtained by finger clip blood oxygen sensor at the initial office visit.
Most patients in the study have at least one prior unenhanced chest CT for
confirmation of PAVM. In addition, some have contrast echocardiography performed at
Yale and interpreted into grades 1 to 4 by experienced readers. Some patients also have
pulmonary angiography from their transcatheter embolization on file. A few patients also
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have MRIs with gadolinium of the brain with note of any aneurysms. Patients were
evaluated for HHT status through genetic testing. Results of positivity and HHT type
were recorded.
Each patient performed one EST followed by one 6MWT after 30 minutes of rest.
The second 6MWT followed after another 30 minutes of rest. Lastly, patients performed
one more EST following the second 6MWT and another 30 minutes of rest. Therefore,
in total, patients performed two EST and two 6MWT on the same day in the order of first
EST, first 6MWT, second 6MWT, and second EST.
Participating patients were all in stable clinical condition and were New York
Heart Association class I. A physician was present at all times during the exercise
studies. This research protocol was approved by the Yale-New Haven Hospital Human
Investigation Committee.

6-minute walk test protocol
6MWT was conducted under direct physician supervision and according to the
guidelines published by the American Thoracic Society and the American Heart
Association (33). The 6MWT is a practical test that requires a 30-meter long, flat,
straight, enclosed, hard-surfaced hallway but no exercise equipment or advanced training
for technicians. The test is self-paced and assesses functional capacity. Patients choose
their own intensity of exercise and allowed to stop and rest during the test, though none
of the subjects in this study chose to do so.
Before the test began, patients sat at rest in a chair located near the starting
position. There was no “warm-up” period before the test. At the start of the test, resting
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heart rate and oxygen saturation were measure using a Nellcor N-20 pulse oximeter
(Nellcor Puritan Bennett LLC, Boulder, CO), which was placed on the patient’s index
finger. The monitor was then removed to prevent inaccurate readings due to considerable
motion artifact during the walk. In addition, patients were asked to rate their baseline
dyspnea and fatigue on the Borg scale (34). As the timer for six minutes starts, patients
were instructed to walk as much as they can up and down the 30-meter hallway. No one
walked with the patient, and patients were not coached during the test.
After six minutes, patients were instructed to stop. At this time, heart rate and
oxygen saturation were measured once again using a Nellcor N-20 pulse oximeter placed
on the index finger. The total distance walked was recorded. In addition, patients were
asked to rate their post-test dyspnea and fatigue on the Borg scale (34).

Exercise stress test protocol
EST was conducted under direct physician supervision in the Yale-New Haven
Hospital Pediatric Cardiology Exercise Laboratory and in accordance with the consensus
statement by the American College of Cardiology (35).
Patients were instructed to wear or bring comfortable exercise clothing, preferably
shorts, T-shirt, and athletic shoes. In preparation for the test, the patient is fitted with 10
electrodes so that a continuous 12-lead ECG tracing can be obtained during testing.
Before the test begins, resting heart rate was measured by electrocardiographic
monitoring, and oxygen saturation was measured using Nellcor OxiMax N-600 oximeter
with Max-Fast adhesive forehead reflectance sensor with headband (Nellcor).
Participants underwent continuous electrocardiographic, oxygen saturation, and heart rate
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monitoring while undergoing cycle ergometry (Marquette Electronics, Milwaukee, WI)
with step-wise increases of 30 watts of resistance every 2 minutes while maintaining a
continuous cadence of 60–65 revolutions per minute.
EST was concluded when participants experienced leg fatigue, shortness of
breath, or reached 85% of their predicted maximum heart rate. At EST conclusion,
patient heart rate and oxygen saturation were measured, and cycle ergometry resistance
was decreased to 15 watts. Participants were instructed to peddle slowly until their heart
rate reached within 10% of baseline.

Statistical analysis
Descriptive statistics were listed as means with standard deviations. Intraclass
Pearson correlation coefficients (ris), with 95% confidence intervals (CIs) were calculated
to assess test–retest reliability for the following variables for the 6MWT and EST
respectively:
1. Baseline heart rate,
2. Post test heart rate,
3. Baseline oxygen saturation,
4. Post test oxygen saturation,
5. Difference between baseline and post test oxygen saturation.
In addition, the level of resistance in watts on the cycle ergometer that the patient was
able to achieve by the end of EST was recorded as well.
Bland–Altman plots were used to assess agreement between 6MWT and EST at
baseline and at the end of each test for oxygen saturation. Oxygen saturation changes
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during 6MWT and EST were compared with a repeated-measures analysis (adjusted for
patient age, sex, weight, and height) and listed as means with standard errors.
Significance was established with alpha < 0.05. Data were analyzed using Microsoft
Excel 2008 for MAC version 12.0 (Microsoft, Seattle, WA) and SAS 9.2 (Cary, NC).

Results
Patient Characteristics
Twenty-two patients were recruited for the study (Table 1). There were 16
females and 6 males, corresponding to previous literature regarding the female
predominance of HHT. We tested both children and adults, with the oldest patient at 74
years of age. 8 patients were under the age of 18. The average resting oxygen saturation
among all patients was 93.9%.
With the exception of two patients who had only positive contrast
echocardiograms, all other patients had positive chest CT findings for PAVMs. PAVM
status among this cohort included the following: 10 focal (<4 PAVMs), 4 multifocal, 4
diffuse, and 10 previously embolized. All participants completed both sets of 6MWT and
EST without adverse events, and all participants reached 85% of their predicted
maximum exercise tolerance on EST, independent of their baseline and peak exercise
oxygen saturation status.

Reproducibility of 6MWT
The reproducibility of 6MWT was determined by examining intraclass correlation
coefficients with 95% confidence intervals (Table 2). All patients performed two 6MWT
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during the day. With the exception of oxygen saturation difference ri = 0.659 (95% CI
0.346-0.841), all parameters including baseline heart rate, post test heart rate, baseline
oxygen saturation, post test oxygen saturation, distance walked showed reproducibility
significance (p < 0.05) as seen by high intraclass correlation coefficients (ri).
The mean baseline heart rates for all patients were 94.5 and 95 respectively in the
two 6MWTs. The ri for baseline heart rate was 0.829 (95% CI = 0.630-0.925). The
mean post test heart rates were 108.3 and 106.5 respectively, with an ri of 0.940 (95% CI
= 0.863-0.975). The mean baseline oxygen saturations were 93.9% and 94.3%, with an ri
of 0.989 (95% CI = 0.975-0.996). The post test oxygen saturations were 92.2% and
93.0%, with an ri of 0.973 (95% CI = 0.933-0.989). The differences in oxygen saturation
between the baseline and post test values were calculated to determine how much
desaturation occurred with exercise. The values are 1.7% and 1.2% respectively for the
first and second 6MWT, with ri of 0.659 (95% CI = 0.346-0.841). The 6MWT distance
walked was similar between the two tests at 471.1 and 477.5 meters, with ri of 0.942
(95% CI = 0.867-0.975).
Reproducibility can also be seen on Bland-Altman plot of the parameters of the
6MWT. The plot compares exact same parameters between the first and second 6MWT
for each patient. Each patient appears as a point on the graph. The point (x, y) uses the
average of two post test oxygen saturations for each patient for the x-grid point and the
difference between them as the y-grid point. The primary application of the BlandAltman plot is to compare two measurements, and the limits of agreement is specified as
average difference ± 1.96 times standard deviation of the difference.
For instance, the graph of end oxygen saturation of 6MWT compares the values
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of each individual patient’s oxygen saturation at the end of the 6MWT from the first test
to that of the second test (Figure 2). Almost all points are within limits of agreement for
end oxygen saturation.
In addition, the Bland-Altman plot of decrease in oxygen saturation in the two
6MWTs shows good correlation with all but one point inside the limits of agreement
(Figure 3).

Reproducibility of EST
In addition to the 6MWT, reproducibility was investigated for EST also by
examining intraclass correlation coefficients with 95% confidence intervals (Table 3).
Patients performed two EST; therefore, each patient possesses two distinct values for
each parameter. All measurements from the EST showed significant reproducibility (p <
0.05) including baseline heart rate, post test heart rate, baseline oxygen saturation, post
test oxygen saturation, the difference between oxygen saturations pre and post test, and
work in watts on the ergometer.
The mean baseline heart rates for all patients were 90.5 and 91.8 respectively,
with ri of 0.871 (95% CI = 0.717-0.944). The mean post test heart rates were 159.0 and
158.5 respectively, with an ri of 0.941 (95% CI = 0.865-0.975). The mean baseline
oxygen saturations were 95.3% and 95.1%, with an ri of 0.979 (95% CI = 0.950-0.991).
The post test oxygen saturations were 91.8% and 92.3%, with an ri of 0.993 (95% CI =
0.982-0.997). The difference in oxygen saturations between the baseline and post test
values were 3.5% and 2.9% respectively for the first and second ESTs, with ri of 0.836
(95% CI = 0.647-0.928). The work in watts that patients were able to pedal to were

15
114.5 and 113.2 respectively, with ri of 0.941 (95% CI = 0.864-0.975).
Bland-Altman plots for end oxygen saturation of EST is shown comparing the
values of each individual’s oxygen saturation at the end of the first EST to that of the
second EST (Figure 4). All except two points lie within the limits of agreement, which is
the mean difference ± 1.96 times standard deviation of the difference.
Furthermore, decreases in oxygen saturation from each EST is also shown on a
Bland-Altman plot with limits of agreement (Figure 5). Only one patient representation
point is outside the limits of agreement for the decrease in oxygen saturation in EST.

Comparison of 6MWT and EST
The 6MWT and EST parameters were compared with each other. For each
patient, the oxygen saturation at the end of the first 6MWT was compared to the oxygen
saturation at the end of the first EST (Figure 6). The mean of all differences between
each set of two numbers was 0.4, and the standard deviation was 2.5. The limits of
agreement are 5.4 and -4.5. The Bland-Altman is shown with all points lying between
the limits of agreement, showing consistent correlation of the 6MWT and EST.
The second parameter that was compared between the two exercise tests was
decrease in oxygen saturation during the tests (Figure 7). The mean difference was 1.8,
and the standard deviation was 2.2, with limits of agreement at 6.1 and -2.4. Once again,
all patient data points were between the limits of agreement, exhibiting high correlation
of the EST and 6MWT.
Lastly, the average of all baseline oxygen saturations and end oxygen saturations
were compared between the two tests (Figure 8). The average change in oxygen
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saturation for 6MWT was -1.5 with a standard error of 0.7. For EST, the average change
in oxygen saturation from beginning to end of exercise was -3.3 with a standard deviation
of 0.7. A larger drop in oxygen saturation occurred during EST than during 6MWT.

Discussion
Current study shows reproducibility of exercise testing
All twenty-two patients recruited for the current study completed all
testing, including two 6MWTs and two ESTs, without complications. For the 6MWT,
distance walked, heart rate at baseline, heart rate at end of test, and oxygen saturations at
the beginning and end were all reproducible as shown by high Pearson correlation
coefficients. For the EST, heart rate at beginning and end of test, oxygen saturations at
the beginning and end of test, and maximum resistance achieved by the patient were all
reproducible as well. Therefore, we have shown that in patients with known PAVMs the
6MWT and EST provide reliable measurements of physiologic parameters by comparing
the test to itself in the same patients. Both tests are physiologic measures of shunt
fractions. Importantly, while not diagnostic of the presence or absence of shunting, the
previous results from Murphy et al. using the EST in patients with diffuse PAVMs
indicated stability of exercise testing mirrored clinical status. Those who had
enlargement of PAVMs exhibited a change in their exercise study or showed new
symptoms such as fatigue and dyspnea.
When comparing the two tests, all parameters across the two were highly
correlated with large correlation coefficients as well as Bland-Altman plots. When
examining oxygen saturation changes during EST and 6MWT, it appears that oxygen
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saturation decreased more during EST than 6MWT (Figure 8). This is likely due to EST
causing more oxygen extraction during exercise as it is a more strenuous test, where
patients move against increasing resistance.
There were some limitations to this study. First, the sample size was small though
enough power was obtained through statistical measures with significance. Secondly,
testing was obtained during routine outpatient clinic visits, and 6MWT and EST were not
correlated with chest CT, pulmonary angiography, or contrast echo results. Some
patients were returning for follow-up after their transcatheter embolization, and some
have not had repair of their PAVMs. Furthermore, some patients had focal PAVMs
while others had diffuse disease. A strength of the study was that it demonstrated
reliability in patients with treated and untreated, focal and diffuse PAVMs. This has led
to our hypotheses, not yet proven, about the potential value of exercise testing above.

Future directions
The next stage in this investigation may include examining longitudinal changes
in oxygen saturation measurements on EST and 6MWT for each patient; in essence,
using the patient as his or her own control to evaluate the use of exercise testing in
follow-up of PAVMs. The hypothesis would be that once a baseline exercise test has
been performed, any further decreases in exercise tolerance and oxygen saturation may
predict recurrence or enlargement of clinically significant PAVM. At that point, a chest
CT would be performed. This obviates radiation exposure due to CT scans up to once or
twice a year for some patients. Hence, the radiation burden and increased cancer risk
may be decreased in this population that has relied heavily on imaging thus far.
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Furthermore, the exercise test parameters, namely oxygen desaturation amount, may be
correlated to the number of unrepaired or newly diagnosed PAVMs.
Ultimately, this study has demonstrated that EST and 6MWT are reliable
measures of exercise capacity, oxygen saturations, and oxygen decreases during the tests
in patients with existing PAVMs. Benefits of exercise testing include non-invasiveness
and low radiation exposure, especially important in children. Reproducibility of both
tests means HHT patients may seek care from pulmonologists or cardiologists, who are
familiar with each of these respective tests. In addition, the 6MWT is a less strenuous
test, which may be useful for the elderly or severely ill patient who cannot perform the
EST due to fatigue. In short, exercise testing may become an important surrogate for CT
in the continued follow-up of 1) asymptomatic pediatric patients, 2) adult patients with
small PAVMs not requiring embolotherapy, and 3) patients post-embolotherapy after CT
has demonstrated involution of the treated PAVM.

Importance of screening and follow-up in patients with PAVMs
Patients may present to an HHT center through a variety of routes. They may
have already experienced one of the complications of HHT, including stroke, brain
abscess, hemoptysis, hemothorax, gastrointestinal bleeding, and so on (36). They may
also have shown persistent symptoms common in HHT, including epistaxis, clubbing,
dyspnea on exertion, and cyanosis (6,37,38).
In the 1990s, various genetic mutations have been shown to exist in HHT.
Endoglin and activin receptor-like kinase proteins, ENG and ACVRL1 genes
respectively, have been described in HHT type 1 and type 2 (39,40). In addition, Smad4
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protein mutations cause an overlap syndrome of juvenile polyposis and HHT (41). In
addition to those, hundreds of other genetic mutations have been described in HHT (42).
After one family member has been diagnosed with HHT, he or she should receive testing
to identify the proband. After the family’s particular genetic mutation is initially
identified, other members can be tested (43). Therefore, many pediatric patients may
present to HHT centers after DNA testing.
The value of screening for PAVMs lies in the prevention of potential
complications that may occur. Currently, patients may receive grade-based contrast
echocardiography to determine their probability for having PAVMs (44). After contrast
echocardiography is shown to be positive, many patients will undergo a non-contrast
chest CT to detect PAVMs (45). The unenhanced chest CT provides information on the
number and location of PAVMs, the size of feeding arteries for each PAVM, and whether
the PAVMs are diffuse or focal (46).
Patients may require follow-up once diagnosed for many reasons. First of all,
patients who have received transcatheter embolotherapy must follow-up 6 months after
treatment with a chest CT to ensure involution of the PAVM. Secondly, patients with
PAVMs with feeding arteries less than 3mm in diameter are not recommended for
embolotherapy because complications have known to occur in PAVMs with larger
feeding arteries (14,18). These patients with unrepaired PAVMs require follow-up in
case of enlargement of the malformations. This is especially true in the pediatric
population because growth of PAVMs is known to occur during puberty and pregnancy
(47). Due to the availability of genetic mutation testing, patients may be completely
asymptomatic but harbor the gene for HHT. These patients, whether adults or children,
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may benefit from non-invasive follow-up methods without radiation exposure.

Treatment of PAVMs in children
No current guidelines exist regarding treatment and follow-up of PAVMs in
children. There are a number of reasons behind the reservations for treating children with
PAVMs, including both reperfusion after and complications during transcatheter
embolotherapy.
Observations suggest high degree of reperfusion post-therapy in children,
irrespective of device and approach. Extensive studies have found and categorized the
causation of reperfusion following embolotherapy (13,48–51). Most studies have found
persistence or reperfusion of embolized PAVMs in a small numbers of patients and
lesions, typically from 0% to 10% (13,48–51). In a Yale series examining 393 treated
PAVMs, reperfusion was identified in 2.8% or 11 out of 393 PAVMs (14). Reasons for
the residual embolized PAVMs included recanalization (n = 7), accessory feeding artery
(n = 1), collateral perfusion of distal feeding artery from small pulmonary artery branches
(n = 1), and systemic bronchial artery collateral perfusion (n = 2) (14). This series was
comprised of 155 patients, with a mean age of 45, and only 7 patients were children
younger than 18 years of age (14).
Studies show the higher reperfusion rate in children as an estimated 15% most
likely due to the higher rate of collateral perfusion development in the pediatric
population (52). In a pediatric series of the 23 children who experienced reperfusion,
collateral perfusion (n = 12), recanalization (n = 11), and missed accessory (n = 8) were
contributing factors (52). Collateral perfusion occurs in a growing lung and resembles
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the collateralization in high flow peripheral arteriovenous malformations.
In addition to reperfusion, some rare complications estimated at 2% can happen
during transcatheter embolotherapy (14,53,54). Complications include angina, transient
ischemic attack, and pleurisy (14,53). A meta-analysis of PAVMs in 130 children
between 1966 and 2000 showed that complications from PAVMs did not occur in
children under 12 years of age who were not cyanotic or clubbed (55). Clinical features
indicative of sizable PAVMs in children can appear as cyanosis, growth failure,
pseudoasthma, or pulse oximetry consistently below 97%.
Because of this higher reperfusion rate and rare procedural complications along
with the lack of complications in those without symptoms, many asymptomatic children
may be followed conservatively. In recent years, the approach for diagnosis in children
has veered away from blood gases and shunt studies toward standing pulse oximetry and
contrast echocardiography.

Screening for PAVMs
Since the majority of patients with PAVMs have HHT and are at risk of
developing new PAVMs throughout their lifetime, the search for a sensitive and safe
screening tool is critical and ongoing. At present, several screening tests are used to
detect the presence of PAVMs. The initial screenings tests include transthoracic contrast
echocardiography (Figure 1) and unenhanced spiral chest computed tomography. Threedimensional helical CT permits a detailed evaluation of PAVMs without contrast
injection, thus preventing accidental intravenous air entry as well. In a series of 37
PAVMs, analysis of the angioarchitecture of 28 PAVMs (76%) was provided by 3D
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reconstructions, while addition of transverse sections to the interpretation led to accurate
evaluation of 35 PAVMs (95%) (56). Other benefits of unenhanced CT over pulmonary
angiography include its noninvasive nature and no contrast requirement.
In recent years, contrast echocardiography has been compared to unenhanced
spiral CT. Agitated saline solution transthoracic contrast echocardiography was shown to
have a sensitivity of 92% to 100% in the detection of PAVMs (57,58). In comparison to
the unenhanced CT, contrast echocardiography is much more sensitive; in fact, it is the
most sensitive test for detection of PAVMs (57,58). It requires minimal invasiveness in
terms of intravenous saline injection but does not expose patients to radiation. In
addition, increased shunt grade seen as microbubbles seen in the left ventricle after a
certain number of cardiac cycles can be used to predict the probability of PAVMs (19).
Four HHT centers, including ones in Italy, Spain, Toronto, and the Netherlands,
have validated the contrast echocardiography in its predictive value of PAVMs (45,58–
60). In the initially validation study at the Toronto center, the positive predictive value of
grades 1, 2, 3, and 4 for the presence of a PAVM were determined to be 0.02, 0.25, 0.56,
and 1.0 respectively (19). The Dutch HHT center investigated echocardiography only in
three grades with the positive predictive value of shunt grade for the presence of PAVMs
on chest high-resolution CT scans as 0.229 for grade 1, 0.348 for grade 2, and 0.830 for
grade 3 respectively (59). Lastly, the Italian center showed an extensive quantitative
analysis of shunt size according to contrast echocardiography degree of opacification of
the left chambers of the heart (45). The overall diagnostic performance of contrast
echocardiography had sensitivity of 1.00, specificity of 0.49, positive predictive value of
0.32, and negative predictive value of 1.00 (45). The positive predictive value for the
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different grades was 0.00 for grade 1, 0.56 for grade 2, 1.00 for grade 3 (45). The
negative predictive value of grade 0 was 1.00 (45).
However, contrast echocardiography is not useful after treatment due to positivity
after repair. In a prospective study, 29 patients underwent contrast echocardiography
prior to and after transcatheter embolization (20). In all patients, contrast echo was
positive prior to therapy. After all PAVMs with feeding vessels greater than 3 mm were
successfully occluded based on completion angiography, 48% of patients showed no
detectable residual PAVMs while others had PAVMs smaller than 3 mm remaining (20).
After repair, 90% of patients showed positive contrast echo results (20). In the subset of
patients with no remaining PAVMs on angiography, 80% continued to show positive
echo results (20). This indicates residual PAVMs too small to be seen on angiography.
The persistence of positive contrast echo results has important implications for the
follow-up and management of HHT patients.
Current international guidelines for the diagnosis and management of HHT
recommends either transthoracic contrast echocardiography at a center of excellence with
expertise in reading echocardiography studies or unenhanced multidetector thoracic CT
with thin-cut of 1–2mm reconstructions (17). While the contrast echocardiography does
not expose patients to radiation, it only provides the probability of PAVM existence in a
patient. The unenhanced chest CTs exposes patients to radiation, which for pediatric
patients can accumulate to a high amount over the years (61). There have not been clear
guidelines for safe and effective screening in the pediatric population. Therefore, HHT
centers employ a combination of clinical evaluation, supine and upright pulse oximetry,
contrast echocardiography, or unenhanced CT.
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Effects of radiation exposure from imaging techniques
In the past few years, the risk of radiation from diagnostic imaging has been
increasingly studied. Because of the ease of use, CT scans have increased dramatically.
An estimated 62 million CT scans are now completed annually in the United States
compared to 3 million in 1980 (61). The postulated mechanism of biological damage is
through formation of hydroxyl radicals from x-ray interactions with water molecules, and
these radicals may interact with nearby DNA causing strand breaks or base damage (61).
In a study of nearly 1 million nonelderly adults in the United States,
approximately 70% of the population underwent at least one medical imaging procedure
with radiation exposure in the three-year study period (62). This resulted in mean
effective doses double what would be expected from natural sources. Generalized to the
population, an estimated 4 million Americans receive effective doses that exceed 20 mSv
per year (62).
Much of the epidemiological data regarding radiation exposure comes from the
cohort of atomic bomb survivors (63–65). The mean dose in this subgroup was about 40
mSv, almost tantamount the organ dose from a typical CT scan involving two to three
scans in an adult (65). In addition, radiation-induced cancer risks have been shown in a
large-scale 15-country study of 400,000 radiation workers in the nuclear industry (66,67).
The workers sustained an average of 20 mSv (66). A significant association was found
between mortality from cancer in both these cohorts (64,67). Through epidemiologic
extrapolation, 1.5 to 2.0% of cancers in the United States today may be caused by
radiation from CT studies (61).
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Because of they carry the diagnosis of HHT, patients and their families have
reported countless instances of receiving CT scans at outside hospitals, most often in the
emergency department. The importance of radiation exposure is paramount in the
pediatric population as cancer risk increases with lower age of exposure due to the
latency periods for solid tumors are typically decades (61) (Figure 9). Children have
more dividing cells and are therefore more radiosensitive, and this is very important for
our pediatric HHT population as they may receive multiple chest CTs to follow PAVMs.
Exercise testing obviates radiation exposure risks associated with CT scans. The
HHT center at Yale piloted exercise testing in the diffuse PAVM group. Annual exercise
testing was found to be a reasonable method to follow this high risk group of patients.
The pilot study also exhibited the safety of performing EST in patients with PAVMs (24).
Having a large pediatric population in our HHT center and having shown the
reproducibility of EST and 6MWT, we hope to use these exercise methods to follow
asymptomatic pediatric patients and assure parents regarding their children’s exercise
capacity. Exercise testing can also be used in adults who are post-repair or have small
PAVMs that have not been treated.

Manifestations of PAVMs in children with HHT
Children who have complications resulting from PAVMs often show clinical
signs of cyanosis, clubbing, or dyspnea on exertion. In a complete literature review of
130 children under age 18 with PAVMs from 1966 to 2000, some patients experienced
complications of hemoptysis or hemothorax (14/130), cerebral abscess (7/130), and
stroke (5/130) (55). However, no child under age 12 had serious complication unless he
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or she was showing signs of cyanosis or clubbing (52).
In a literature search of reports since 2000, two main case series were found. In
one long-term study over 16 years, eight children with PAVMs from age 1 day to 12
years were included (68). The most frequent presenting symptoms were pulmonary (n =
6), including dyspnea on exertion and hemoptysis. The others showed neurologic
complications at initial presentation. The complications from PAVMs included
hemoptysis/hemothorax (n = 6), cerebral abscess (n = 5), and stroke (n = 1). Importantly,
on clinical examination, all children showed signs of cyanosis (n = 8). Some showed
dyspnea on exertion (n = 6) and/or clubbing (n = 3). Their measured oxygen saturations
ranged from 59% to 80%.
In a separate case series, six children under 12 years old were reported (69). Five
of these patients initially presented with cyanosis and were treated with transcatheter
embolotherapy. One patient presented with hemoptysis, though oxygen saturation and
other clinical signs of low oxygen were not reported. In summary, all children under 12
years of age that have had complications showed signs of cyanosis, clubbing, or dyspnea
on exertion. The clinical characteristics of 149 children under age 18 reported in
literature until 2007 have been summarized (Table 4).

Cerebral manifestations of HHT in children
Children from families with HHT are screened for existence of PAVMs, and
conversely children with PAVMs should be screened for HHT. The hereditary aspect of
HHT means family members of those with HHT also need screening for HHT. Although
PAVMs cause morbidity and mortality, many other organ systems are also affected by
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HHT.
Cerebral arteriovenous malformations (CAVMs) occur in the brain with a
prevalence of 5% to 20% in adults and children affected by HHT (8,70). Morgan et al.
reported on several cases of intracranial hemorrhage secondary to CAVMs in infants and
children (70). None of the nine children, who presented with intracranial hemorrhage
secondary to cerebral AVM, were suspected of having HHT before the hemorrhage
despite family history of the disease (70). All cases were confirmed through autopsy,
imaging studies, or surgery to have been CAVMs causing intracranial hemorrhage (70).
The youngest of these children was a neonate born at 38.5 weeks with low Apgar scores
and dilated pupils, and he was found to have a massive left parietal occipital hemorrhage
(70). In six of nine families, the endoglin mutation for HHT type 1 was found (70). The
other three children came from families containing relatives with HHT diagnoses using
the Curacao criteria (70). No clinical indications of CAVM existed prior to intracranial
hemorrhage, which resulted in death of five children, cognitive and motor impairment in
three, and hemiparesis in one (70).
In the series from Yale, five of 34 children showed a CAVM on brain imaging
(55). Two of five were treated with surgery (55). Eight children were not screened (55).
Of these, two developed intracranial hemorrhage, resulting in one with hemiparesis and
one who fully recovered (55).
Most often patients are asymptomatic before intracranial hemorrhage occurs. If
symptomatic, patients may experience migraine headaches, visual changes, mental status
changes, seizures, intracranial hemorrhages, transient ischemic attacks, and strokes (70–
73). Intracranial hemorrhages from CAVMs are devastating and have been reported as
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the leading cause of death in the pediatric HHT population (74). If the patient survives,
he or she may suffer from significant neurological deficits in later life (70). Infants and
children with a family history of HHT are at risk for sudden and catastrophic intracranial
hemorrhage.
The prevalence of CAVMs larger than 10 mm in diameter is estimated to be 12%
and 11% by two respective studies by Willemse et al. and Fulbright et al (8,75).
Although the risk of massive hemorrhage in children with HHT is uncertain, some
estimates from 2% to 4% per year in the pediatric populations affected by HHT (70). A
prevalence rate of greater than 10% for larger CAVMs along with a risk of hemorrhage
support the screening for CAVMs in all patients with HHT in order to help identify and
prevent severe sequelae. One standard gadolinium-enhanced brain MRI is used to screen
the presence of CAVMs in HHT patients.

Gastrointestinal manifestations of HHT in children
Fewer than two percent of HHT patients present with gastrointestinal symptoms
prior to 30 years of age (76). Gastrointestinal bleeding usually appears in 20% of HHT
patients at a mean age of 50-60 (76–79). Gastrointestinal manifestations are the initially
presentation of HHT in less than 1% of HHT patients (76). Bleeding is often painless
and may arise from arteriovenous malformations or telangiectasias throughout the GI
tract. Bleeding from telangiectasias has been reported in four children from 1 to 5 years
of age (80).
In addition, hemobilia is rare in children; however, Bross et al. reported on a 21month-old child who presented with gastrointestinal bleeding due to hemobilia secondary
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to hepatic and biliary arteriovenous malformations (81). A 14-year-old girl with an HHT
positive family history was reported to have persistent bright red blood per rectum (76).
No findings were evident on colonoscopy and esophagastroduodenoscopy (76). A rightsided ileocolectomy was performed, and typical lesions were found on pathology (76).
Endoscopic findings typically include multiple well-defined erythematous flat nodules in
the stomach, duodenum, small bowel, or colon that may require eletrocoagulation, which
is not helpful in the long-term (81–83).
Previously, juvenile polyposis (JP) and HHT were considered clinically very
distinct diseases caused by mutations in SMAD4 and BMPR1A, for JP, and endoglin and
ALK1, for HHT (47,84–86). Recently, a combined syndrome of JP-HHT was described
that is also caused by mutations in SMAD4 (87). Any mutation in SMAD4 can cause JPHHT (88). Therefore, any JP patient with a SMAD4 mutation is at risk for GI
manifestations of HHT and any HHT patient with SMAD4 mutation is at risk for early
onset gastrointestinal cancer (87,88). In short, a patient who tests positive for a SMAD4
mutation should be monitored accordingly with regard to risks for the combined JP-HHT
syndrome.

Yale algorithm for children under 12
The evidence from extensive review of all pediatric cases at Yale prior to the year
2000 and review of literature on pediatric HHT cases post 2000 shows that no
asymptomatic child under 12 years of age has had a complication from PAVM
(52,55,68,69). Children who have had complications showed signs of low oxygenation
whether cyanosis or low pulse oximetry (52,55,68,69).
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The Yale algorithm for children with HHT was developed based on previous
literature and past experience at our center. All patients are given an initial 90-minute
history and physical clinical appointment, during which careful examination for
telangiectasia is performed along with a standing pulse oximetry. Patients are
recommended for genetic testing as PAVMs occur in all genotypes associated with HHT.
The crucial piece of imaging that all children and adults need is a brain MRI with
gadolinium. Brain MRI is performed due to the silent nature of CAVMs as previously
mentioned, and patients may develop an intracranial bleed at any age (70).
Next, an exercise test is performed to obtain baseline oxygenation during activity.
If patients show a standing pulse oximetry above 98% with no symptoms of dyspnea,
cyanosis, clubbing, and no desaturation is observed during the exercise test, then further
investigation including contrast echocardiography and unenhanced CT would be
discouraged. Sometimes, at the insistence of parents, contrast echocardiography would
be performed.
However, if desaturation occurs or the patient shows symptoms of low
oxygenation, a contrast echo is warranted. If contrast echocardiography reveals grade 2
or above, an unenhanced chest CT would be performed to search for PAVMs. In the case
of a family member having recent brain abscess, contrast echocardiography would be
recommended to an asymptomatic child. With a grade 1 echo result, no further
investigation is warranted. Due to the rarity of GI manifestations in children, it is not part
of the algorithm to screen for arteriovenous malformations in the GI tract or liver.
Once again, there are no guidelines for screening and follow-up in the pediatric
HHT population. Our center proposes to expand exercise testing and encourage
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participation from other centers in the validation and use of the exercise protocols shown
to be reproducible here.
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Figure 1. Contrast echocardiography grading scale for PAVMs.
Echocardiography grading shows increased shunt grade seen as microbubbles in the left
ventricle after a certain number of cardiac cycles can be used to predict the probability of
PAVMs (19).
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Figure 2. Oxygen Saturation at End of 6MWT.
The Bland-Altman plot of oxygen saturation at the end of both 6MWTs with limit of
agreement defined as mean ±1.96 SD is presented here. The mean difference (solid line)
was -0.8, and the standard deviation was 2.0. Therefore, the limits of agreement (dotted
lines) are 3.2 and -4.8.
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Figure 3. Decrease in Oxygen Saturation during Six Minute Walk Test.
The Bland-Altman plot of decrease in oxygen saturation during 6MWTs with limits of
agreement defined as mean ±1.96 SD is presented here. The mean difference (solid line)
was -0.5, and the standard deviation was 1.7. Therefore, the limits of agreement (dotted
lines) are 3.0 and -3.9.
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Figure 4. Oxygen Saturation at End of Exercise Stress Test.
The Bland-Altman plot of oxygen saturation at end of ESTs with limits of agreement
defined as mean ±1.96 SD is presented here. The mean difference (solid line) was -0.5,
and the standard deviation was 1.0. Therefore, the limits of agreement (dotted lines) are
1.5 and -2.4.
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Figure 5. Decrease in Oxygen Saturation During EST.
The Bland-Altman plot of decrease in oxygen saturation during ESTs with limits of
agreement defined as mean ±1.96 SD is presented here. The mean difference (solid line)
was -0.6, and the standard deviation was 1.9. Therefore, the limits of agreement (dotted
lines) are 3.1 and -4.3.
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Figure 6. Oxygen Saturation Measured at End of 6MWT and EST.
The Bland-Altman plot of oxygen saturation at the end of 6MWT compared with end of
EST with limits of agreement defined as mean ±1.96 SD is presented here. The mean
difference (solid line) was 0.4, and the standard deviation was 2.5. Therefore, the limits
of agreement (dotted lines) are 5.4 and -4.5.
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Figure 7. Decrease in Oxygen Saturation During 6MWT and EST.
The Bland-Altman plot of the decrease in oxygen saturation during 6MWT compared
with during EST with limits of agreement defined as mean ±1.96 SD is presented here.
The mean difference (solid line) was 1.8, and the standard deviation was 2.2. Therefore,
the limits of agreement (dotted lines) are 6.1 and -2.4.
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Figure 8. Response of Oxygen Saturation to 6MWT and EST.
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m e dic i n e

Figure 9. Estimated Dependence of Lifetime Radiation-Induced Risk of Cancer Versus
Age at Exposure (61).
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Data for twenty-two patients who participated in this study is presented with average sex,
age, weight, height, and resting oxygen saturation levels shown. (a) In parentheses, the
minimum and maximum numbers are entered for each category.
Table 1 Patient characteristics
Sex (F/M)

16/6

Age (y)

28.2 (8.8, 74.3)a

Weight (kg)

64.8 (29.0, 133.8)a

Height (m)

1.6 (1.3, 1.9)a

Resting oxygen saturation (%)

93.9 (63, 100)a

a

Range (minimum, maximum)

123
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Table 2. Mean values with standard deviations (SD) and intraclass correlation
coefficients (ri) with 95% confidence intervals (CI) for 6MWT.
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Table 3. Mean values with standard deviations (SD) and intraclass correlation
coefficients (ri) with 95% confidence intervals (CI) for EST.
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Table 4. Clinical Characteristics of 144 Children with PAVMs Reported in Literature
under age 18.
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